<DOC>
	<DOCNO>NCT01184599</DOCNO>
	<brief_summary>The purpose study evaluate effect aliskiren , novel direct rennin inhibitor , renal function progress renal disease hypertensive patient IgA nephropathy .</brief_summary>
	<brief_title>A Prospective Study Kidney Protective Effect Aliskiren Hypertensive Patients With IgA Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Glomerulonephritis</mesh_term>
	<mesh_term>Glomerulonephritis , IGA</mesh_term>
	<criteria>IgA nephropathy confirm renal biopsy Hypertension ( &lt; = 125/75 mmHg ) Patients treat angiotensin type 1 receptor blocker angiotensinconverting enzyme inhibitor within 4 week Severe hypertension ( &lt; = 180/110 mmHg ) secondary hypertension Patients history allergy adverse effect aliskiren Renal dysfunction ( estimate Glomerular Filtration Rate &lt; 60 mL/min/1.73m2 ) Pregnancy Patient treat cyclosporine Hyperkalemia ( serum potassium &gt; = 5.6 mmol/L ) Autoimmune disease include systemic lupus erythematosus Patients inadequate study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Aliskiren</keyword>
	<keyword>Albuminuria</keyword>
	<keyword>Angiotensinogen</keyword>
	<keyword>collagen type IV</keyword>
	<keyword>Transforming Growth Factor beta</keyword>
	<keyword>aldosterone</keyword>
	<keyword>renin</keyword>
	<keyword>prorenin receptor</keyword>
	<keyword>des-angiotensin I renin substrate</keyword>
	<keyword>oxidative stress</keyword>
	<keyword>advanced glycosylation end-product receptor</keyword>
	<keyword>N , N-dimethylarginine</keyword>
</DOC>